Facilitating Understanding in Informed Consent
Have you read the draft guidance posted by FDA on Facilitating Understanding in Informed Consent? The key takeaway is that important information that would impact a participant’s decision on whether to participate in a trial should be presented at the beginning of the ICF process. FDA encourages the use of ‘bubbles’ to highlight key information, [...]